CoChat

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk

Patel, Anushka, Cass, Alan, Peiris, David, Usherwood, Tim, Brown, Alex, Jan, Stephen, Neal, Bruce, Hillis, Graham S, Rafter, Natasha, Tonkin, Andrew, Webster, Ruth, Billot, Laurent, Bompoint, Severine, Burch, Carol, Burke, Hugh, Hayman, Noel, Molanus, Barbara, Reid, Christopher M, Shiel, Louise, Togni, Samantha, Rodgers, Anthony, for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration · 2015 · European Journal of Preventive Cardiology
Cited by 182

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether fixed dose combinations of generic drugs ('polypills') would promote use of such medications. METHODS: We conducted a randomized, open-label trial involving 623 participants from Australian general practices. Participants had established CVD or an estimated five-year CVD risk of ≥15%, with indications for antiplatelet, statin and ≥2 blood pressure lowering drugs ('combination treatment'). Participants randomized to the 'polypill-based strategy' received a polypill containing aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg. Participants randomized to 'usual care' continued with separate medications and doses as prescribed by their doctor. Primary outcomes were self-reported combination treatment use, systolic blood pressure and total cholesterol. RESULTS: After a median of 18 months, the polypill-based strategy was associated with greater use of combination treatment (70% vs. 47%; relative risk 1.49, (95% confidence interval (CI) 1.30 to 1.72) p < 0.0001; number needed to treat = 4.4 (3.3 to 6.6)) without differences in systolic blood pressure (-1.5 mmHg (95% CI -4.0 to 1.0) p = 0.24) or total cholesterol (0.08 mmol/l (95% CI -0.06 to 0.22) p = 0.26). At study end, 17% and 67% of participants in polypill and usual care groups, respectively, were taking atorvastatin or rosuvastatin. CONCLUSION: Provision of a polypill improved self-reported use of indicated preventive treatments. The lack of differences in blood pressure and cholesterol may reflect limited study power, although for cholesterol, improved statin use in the polypill group counter-balanced use of more potent statins with usual care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2047487314530382

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 182

Metadata

Authors
Patel, A., Cass, A., Peiris, D., Usherwood, T., Brown, A., Jan, S., Neal, B., Hillis, G. S., Rafter, N., Tonkin, A., Webster, R., Billot, L., Bompoint, S., Burch, C., Burke, H., Hayman, N., Molanus, B., Reid, C. M., Shiel, L., Togni, S., Rodgers, A., & for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration
Venue
European Journal of Preventive Cardiology
Published
2014-03-27
Volume
22
Issue
7
Pages
920-930
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2132701822
Cited by
182
References
8
FWCI
20.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. https://app.cochat.ai/papers/10.1177/2047487314530382
The paper
Patel, A., Cass, A., Peiris, D., Usherwood, T., Brown, A., Jan, S., Neal, B., Hillis, G. S., Rafter, N., Tonkin, A., Webster, R., Billot, L., Bompoint, S., Burch, C., Burke, H., Hayman, N., Molanus, B., Reid, C. M., Shiel, L., . . . for the Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. (2015). A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487314530382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.